Document is current

Any future updates will be listed below

Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

Crossref DOI link: https://doi.org/10.1007/s40265-022-01805-0

Published Online: 2022-11-07

Published Print: 2022-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark